|
| operating_income = US$ -50.499 million (2015)〔 | net_income = US$ -50.358 million (2015)〔 | assets = US$ 97.464 million (2015)〔 | equity = US$ 97.646 million (2015)〔 | num_employees = 215 (April 30, 2015)〔 | homepage = (www.peregrineinc.com ) }} Peregrine Pharmaceuticals, Inc. is an American biopharmaceutical company with a portfolio of monoclonal antibodies in clinical trials focused on developing therapeutics to stimulate the body's immune system to fight cancer. Peregrine is pursuing multiple clinical programs in cancer with their lead immunotherapy product candidate bavituximab. Peregrine also has in-house cGMP manufacturing capabilities through its wholly owned subsidiary Avid Bioservices, Inc., which provides development and biomanufacturing services for both Peregrine and outside customers.〔http://www.peregrineinc.com/about-us/overview.html〕 ==History== Peregrine was founded in June 3, 1981 under its former name Techniclone International Corporation, a California corporation. On March 24, 1997, Techniclone International Corporation was merged with and into Techniclone Corporation, a corporation incorporated in the State of Delaware on September 25, 1996. This merger was effected for the purpose of effecting a change in the Company's state of incorporation from California to Delaware. The Company changed its name from Techniclone Corporation to Peregrine Pharmaceuticals, Inc. in October 2000.〔http://ir.peregrineinc.com/faq.cfm〕 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「Peregrine Pharmaceuticals」の詳細全文を読む スポンサード リンク
|